Myasthenia gravis (MG) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Myasthenia gravis (MG)

Myasthenia gravis (MG) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Myasthenia gravis (MG) are broadly classified as,

Early-onset MG: age at onset <50 years. Thymic hyperplasia, usually females,

Late-onset MG: age at onset >50 years. Thymic atrophy, mainly males,

Thymoma-associated MG (10%–15%)

MG with anti-MUSK antibodies,

Ocular MG (oMG): symptoms only affecting extraocular muscles,

MG with no detectable AChR and muscle-specific tyrosine kinase (MuSK) antibodies.

According to Thelansis Epidemiology research study, autoimmune myasthenia gravis has a prevalence of approximately 22-43 per 100,000 individuals in the United States.

Competitive landscape of Myasthenia gravis (MG) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Myasthenia gravis (MG) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Myasthenia gravis (MG) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Myasthenia gravis (MG) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company                                 Stage

1        Soliris        Alexion Pharmaceuticals, Inc. (ALXN)        Approved

2        Prograf        Astellas Pharma, Inc. (4503:JP)        Approved in other than U.S./E.U.

3        Venoglobulin IH        Mitsubishi Tanabe Pharma Corporation (4508:JP)        Approved in other than U.S./E.U.

4        Efgartigimod        argenx N.V. (ARGX)        III

5        Firdapse        Catalyst Pharmaceuticals Inc. (CPRX)        III

6        Ultomiris        Alexion Pharmaceuticals, Inc. (ALXN)        III

7        CV-MG01        CuraVac, Inc        II/III

8        ACT-101        Alpha Cancer Technologies, Inc.        II

9        Benlysta        GlaxoSmithKline plc (GSK)        II

10        Iscalimab        Novartis AG (NVS)        II

11        Nipocalimab        Momenta Pharmaceuticals, Inc. (MNTA)        II

12        Rozanolixizumab        UCB SA (UCB:BB)        II

13        RVT-1401        Roivant Sciences, Inc.        II

14        Zilucoplan        Ra Pharmaceuticals, Inc. (RARX)        II

15        GTP-004        GT Biopharma Inc. (GTBP)        I

16        Inebilizumab        Viela Bio        I

17        Hizentra        CSL Limited (CSL:AU)        Investigator Initiated

18        Rituxan        Roche Holding AG (RHHBY)        Investigator Initiated

19        ALN-CC5        Alnylam Pharmaceuticals, Inc. (ALNY)        Preclinical

20        ALXN1830        Alexion Pharmaceuticals, Inc. (ALXN)        Preclinical

21        Myasthenia Gravis Vaccine (UPenn)        University of Pennsylvania        Preclinical

22        PRTX-100        Protalex, Inc. (PRTX)        Preclinical

23        Regenemab        Regenesance Inc.        Preclinical

24        RPI-78M        Nutra Pharma Corp. (NPHC)        Preclinical

25        TOL2        Toleranzia AB (TOL:SS)        Preclinical